Itraconazole (Sporanox®) in superficial and systemic fungal infections

References

• Rewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch. Dermatol 133, 1172–1173 (1997).
   PubMedGoogle Scholar
• Chiritescu MM, Chiritescu ME, Scher RK. Newer systemic antifungal drugs for the treatment of onychomycosis. Clin. Pediatr. Med. Surg 13, 741–758 (1996).
   PubMedGoogle Scholar
• Rewski BE. Onychomycosis. Treatment, quality of life and economic issues. Am. J. Clin. Dermatol 1, 19–26 (2000).
   Google Scholar
• Del Rosso JQ, Current management of onychomycosis and dermatomycoses. Curr. Infect. Dis. Rep. 2, 438–445 (2000).
   PubMedGoogle Scholar
• De Doncker P Itraconazole and terbinafinein perspective: from petri dish to patient. J. Eur. Acad. Dermatol Wrzereol 12 (Suppl. 1), S10—S16 (1999).
   Google Scholar
• Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev. Infect. Dis. 9\(Suppl. 1), 15-32(1987).
   PubMedGoogle Scholar
• Fromtling RE (Ed.), JR Prous Science Publishers, SA, USA 117–192 (1987).
   Google Scholar
• Gupta AK, Lambert J, Revuz J, Shear N. Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur. j Dermatol 11, 6–10 (2001).
   Google Scholar
• Gupta AK Pharmacoeconomic analysis oforal antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis. Pharmaco economics 13,243–256 (1998).
   PubMedGoogle Scholar
• Pierard GE, Arrese JE, Pkrard-Franchimont C. Itraconazole. E. Opin. Pharmacother. 1,287–304 (2000).
   PubMedGoogle Scholar
• ••Recent comprehensive review ofitraconazole.
   Google Scholar
• Scher RK Onychomycosis: therapeutic update. J. Arn. Acad. Dermatol 40, S21—S26 (1999).
   Web of Science ®Google Scholar
• ••Overview of antifungal treatment foronychomycosis.
   Google Scholar
• Vanden Bossche H, Koymans L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther. 67,79–100 (1995).
   PubMed Web of Science ®Google Scholar
• Vanden Bossche H, Marichal P Odds FC. Molecular mechanisms of drug resistance in fungi. Trends. Microbial 2,393–400 (1994).
   PubMedGoogle Scholar
• Vanden Bossche H, Marichal P Le Jeune L, et al Effects of itraconazole on cytochtDme P450-dependent sterol 14 a-demethylation and reduction of 3-ketosteroids in Gyptococcus rzeofirmans. Arztimicrob. Agents Chemother. 37,2101–2105 (1993).
   Web of Science ®Google Scholar
• Vanden Bossche H, Marichal P Gorrens J, et al Interaction of azole derivates with cytochrome P450 isoenzymes in yeast, fungi, plants and mammalian cells. Pestic. Sri 21,289–306 (1987).
   Google Scholar
• Baily EM, Krakovsky DJ, Rybak MJ. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 10,146–153 (1990).
   PubMed Web of Science ®Google Scholar
• Caputo R, Barbareschi M. Itraconazole: new horizons. [Giornak Italian° di Dermatologia e Venereologia] 137,1–7 (2002).
   Google Scholar
• Steinhilber D, Jaschonek K, Knopse J, Morof O, Roth HJ. Effects of novel antifungal azole derivates on the 5-lipooxygenase and cyclooxygenase pathway. Arzneimittelforschurzg 40,1260–1263 (1990).
   PubMed Web of Science ®Google Scholar
• Bremm KD, Plempel M. Modulation of leukotriene metabolism from human polymorphonuclear granulocytes by bifonazole. Micoses 34,41–45 (1991).
   PubMed Web of Science ®Google Scholar
• Heykants J, Van Peer A, Van De Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview Micoses 32(Suppl. 1), 67–87 (1989).
   Google Scholar
• De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 61\(Suppl. 1), 27–37 (2001).
   PubMed Web of Science ®Google Scholar
• ••Review of the pharmacology of thedifferent itraconazole formulations.
   Google Scholar
• Grant SM, Clissold SR Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 37,310–344 (1989).
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of itraconazole pharmacodynamics, pharmacokinetics and therapeutic use.
   Google Scholar
• Cauwenbergh G. Skin kinetics of azole antifungal drugs. Curr. Top. Med Micol. 4, 88–136 (1992).
   PubMedGoogle Scholar
• Cauwenbergh G, Degreef H, Heykants J, et al Pharmacokinetic profile of orally administered itraconazole in human skin. J. Am. Acad. Dermatol 18,263–268 (1988).
   PubMed Web of Science ®Google Scholar
• Matthieu L, De Doncker P, Cauwenbergh G, et al. Itraconazole penetrates the nail via the nail matrix and the nail bed — an investigation in onychomycosis. Clin. E. Dermatol 16,374–376 (1991).
   PubMed Web of Science ®Google Scholar
• Poirer JM, Cheymol G. Optimization ofitraconazole therapy using target drug concentrations. Clirz. Pharmacokinet. 35, 461–473 (1998).
   PubMedGoogle Scholar
• Boelaert J, Schurgers M, Matthys E, et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Arztimicrob. Agents Chemother. 32,1595–1597 (1988).
   PubMed Web of Science ®Google Scholar
• Barone JA, Moskovitz BL, Guarnieri J, et al Enhanced bioava ilability of itraconazole in hydroxypropyl-B-cydodextrin solution versus capsules in healthy volunteers. Arztimicrob. Agents Chemother. 42, 1862–1865 (1998).
   PubMed Web of Science ®Google Scholar
• Van de velde VJS, Van Peer AP, Heykants JJP, et al Effect of food on the pharmacokinetics of a new hydroxypropyl-B-cydodextrin formulation of itraconazole. Pharmacotherapy 16,424 428 (1996).
   Web of Science ®Google Scholar
• Barone JA, Moskovitz BL, Guarnieri J, et al Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 18,295–301 (1998).
   PubMed Web of Science ®Google Scholar
• Reynes J, Bazin C, Nana F, et al Pharmacokinetics of itraconazole (oral solution) in two groups of human immuno-deficiency virus-infected adults with oral candidiasis. Arztimicrob. Agents Chemother. 41,2554–2558 (1997).
   PubMed Web of Science ®Google Scholar
• De Doncker P, Gupta AK, Matynissen G, Stoffels P Heremans A. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J. Am. Acad Dermatol 37,696–974 (1997).
   Web of Science ®Google Scholar
• Chow KW, Ting HC, Yen PY, et al Short treatment schedules of itraconazole in dermatophytosis. Int. J. Dermatol 37, 446–448 (1998).
   PubMed Web of Science ®Google Scholar
• Bonifaz A, Saul A. Treatment of tinea pedis with a single pulse of itraconazole. Eur. Dermatol 12,157–159 (2002).
   PubMed Web of Science ®Google Scholar
• Hainer BL Dermatophyte infections. Am. Fain. Physician 67,101–108 (2003).
   PubMed Web of Science ®Google Scholar
• ••Overview of dermatophyte fungalinfections and their treatment.
   Google Scholar
• Gupta AK, Hofstader SLR, Adam P Summerbell RC. Tinea capitis: an overview with emphasis on management. Pediatr. Dermatol 16,171–189 (1999).
   PubMed Web of Science ®Google Scholar
• De Doncker PRG, Scher RK, Baran RL, et al Itraconazole therapy is effective for pedal onychomycosis caused by some non-dermatophyte moulds and in mixed infection with dermatophytes and moulds: a multicenter study with 36 patients. J. Am. Acad. Dermatol 36,173–177 (1997).
   PubMed Web of Science ®Google Scholar
• Summerbell RC. Epidemiology andecology of onychomycosis. Dermatology 194\(Suppl. 1), 32–36 (1997).
   PubMed Web of Science ®Google Scholar
• Del Rosso JC, Gupta AK Oral antifungal agents: recognition and management of adverse reactions. Todays Therapeutic Trerzds 15,75–84 (1997).
   Google Scholar
• Odom RB, Aly R, Scher RK, et al A multi-center, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis in the fingernail. J. Am. Acad. Dermatol 36,231–235 (1997).
   PubMed Web of Science ®Google Scholar
• Firooz A, Kbamesipour A, Dowlati Y. Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis.j Dermatol Treat. 14, 95–98 (2003).
   PubMedGoogle Scholar
• Arca E, Tastan HB, Akar Kurumlu Z, Gur AR An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis.j Dermatol Treat. 13,3–9 (2002).
   PubMed Web of Science ®Google Scholar
• Jain S, Sehgal VN. Itraconazole versus terbinafine in the management of onychomycosis: an overview. J. Dermatol Treat. 14,30–42 (2003).
   PubMedGoogle Scholar
• ••Comparison of all aspects and propertiesof itraconazole and terbinafine in the treatment of onychomycosis.
   Google Scholar
• Kejda J. Itraconazole pulse therapy versus continuous terbinafine dosing for toenail onychomycosis. Postgrad. Med. Spec. No, 12–15 (1999).
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Billstein S, Rantanen T, et al LION study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil versus itraconazole in onychomycosis. Br. J. Dermatol 141\(Suppl. 56), 5–14 (1999).
   PubMedGoogle Scholar
• Sergeev AY, Gupta AK, Sergeev YV The Scoring Clinical Index for Onychomycosis (SCIO index). Skin Therapy Lett. 7\(Suppl. 1), 6–7 (2002).
   PubMedGoogle Scholar
• •Presentation of a composite index to score the overall severity of onychomycosis in view of therapy choice and comparability of clinical trials.
   Google Scholar
• Evans EGV. The rationale for combination therapy. Br. J. Dermatol 145\(Suppl. 60), 9–13 (2001).
   PubMedGoogle Scholar
• Hay RJ. The future of onychomycosis therapy may involve a combination of approaches. Br. J. Dermatol 145\(Suppl. 60), 3–8 (2002).
   Google Scholar
• Gupta AK, Lpide CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad Dermatol 44, 485–491 (2001).
   PubMed Web of Science ®Google Scholar
• •Results of a clinical trial using sequential combination therapy for onychomycosis.
   Google Scholar
• Bodey GP (Ed.), Raven Press, NY, USA 225–247 (1993).
   Google Scholar
• Holland J, Young ML, Lee O, C-A Chen S. Vulvovaginal carriage of yeasts other than C,anc&da albicans. Sex. Transm. Infect. 79, 249–250 (2003).
   PubMed Web of Science ®Google Scholar
• Bauters TGM, Dhont AM, Temmerman MIL, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am. J. Obstet. Gynecol 187, 569–574 (2002).
   PubMed Web of Science ®Google Scholar
• Hay RJ. The management of superficial candidiasis. J. Am. Acad Dermatol 40, S35—S42 (1999).
   Web of Science ®Google Scholar
• Wesel S. Itraconazole: a single-day oral treatment for acute vulvovaginal candidosis. Br. J. Cli,z. Pract. 44\(Suppl. 71), 77–80 (1990).
   Google Scholar
• Roongpisuthipong A, Sentrakul Bhiraleus P, et al. Itraconazole in the treatment of vulvovaginal candidosis. Med. Assoc. Thai. 15,30–34 (1992).
   Google Scholar
• Del Rosso JQ, Zelfis S, Gupta AK Itraconazole in the treatment of superficial cutaneous and mucosal Carzdida infections. J. Am. Osteopath. Assoc. 98,497–502 (1998).
   PubMedGoogle Scholar
• Alcantara R, Garibay JM. Itraconazoletherapy in dermatomycoses and vaginal candidiasis: efficacy and adverse effects profile in a large multicenter study. Adv. Then 5,326–334 (1998).
   Google Scholar
• Woolley PD, Hiyins SP Comparison of dotrimazole, fluconazole and itraconazole in vaginal candidiasis. Br. J. an. Pract. 49, 65–66 (1995).
   PubMedGoogle Scholar
• Mikamo H, Kawazoe K, Sato Y, Hayasaki Y, Tamaya T Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis. Chemotherapy 44,364–368 (1998).
   PubMed Web of Science ®Google Scholar
• Singson-alday AP, Ortega AR A single blind comparative study between itraconazole and fluconazole in the one-day treatment of vulvo-vaginal candidiasis. Philipp. J. Obstet. Gynecol 22,119–121 (1998).
   PubMedGoogle Scholar
• Cartledge JD, Midgely J, Gazzard BG. Itraconazole oral solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency sydrome patients with candidosis.j Clin. Pathol 50, 477–480 (1997).
   PubMed Web of Science ®Google Scholar
• Reynes J, Raffi F, Joly V, et al Itraconazole oral solution for treatment of fluconazole resistant oral/esophageal candidosis in HIV-infected patients: results of a prospective multicenter study. I. Clinical assessment. J. Med Mzcol. 9,83–87 (1999).
   Google Scholar
• Eichel M, Just-Nubling G, Helm EB, Stille W Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis. Mxoses 39\(Suppl. 1), 102–106 (1996).
   Google Scholar
• Koks CH, Meenhorst PL, Bult A, Beijnen JH. Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons. Pharmacol Res. 46,195–201 (2002).
   PubMed Web of Science ®Google Scholar
• Delrosso JQ, Gupta AK (1999) Oral itraconazole therapy for superficial, subcutaneous and systemic infections. A panoramic view. Postgrad. Med. Spec No, 46–52 (1999).
   Google Scholar
• ••Overview of itraconazole treatmentregimens for various fungal infections.
   Google Scholar
• Gupta AK, Kohli Y, Li A, Faergemann J,Summerbell RC. In vitro susceptibility of the seven Malassezia species to ketaconazole, voriconazole, itraconazole and terbinafine. Br. J. Dermatol 142, 758–765 (2000).
   PubMed Web of Science ®Google Scholar
• Galimberti RE, Villalba I, Galarza S, Raimondi A, Flores V Itraconazole in pityriasis versicolor: ultastructural changes in Malassezia furfur produced during treatment. Rev. Infra. Dis. 9\(Suppl. 1), S134—S138 (1987).
   Google Scholar
• Faergemann J, Gupta AK, Al Mofadi A, Abanami A, Shareaah AA, Marynissen G. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch. Dermatol 138,69–73 (2002).
   PubMed Web of Science ®Google Scholar
• Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am. J. Clin. Dermatot 1, 75–80 (2000).
   Google Scholar
• •Summary of seborrheic dermatitis and pityriasis versicolor and their respective treatment options.
   Google Scholar
• Potter BS, Burgoon CF jr, Johnson WC. Pityrosporum folliculitis. Report of 7 cases and review of the Pityrosporum organism relative to cutaneous disease. Arch. Dermatol 107,388–391 (1973).
   PubMedGoogle Scholar
• Back O, Faergemann J, Homqvist R Pityrosporum folliculitis: a common disease of the young and middle-aged./ Am. Acad. Dermatol 12,56–61 (1985).
   PubMed Web of Science ®Google Scholar
• Jillson OE Pityrosporum folliculitis. Cutts 35,226–227 (1985).
   PubMed Web of Science ®Google Scholar
• Jacinto-Jamora S, Tamesis J, Katigbak ML Pityrosporum folliculitis in the Philippines: diagnosis, prevalence and management. J. Am. Acad. Dermatol 24,693–696 (1991).
   PubMed Web of Science ®Google Scholar
• Yu HJ, Lee SK, Son SJ, Kim YS, Yang HY, Kim JH. Steroid acne vs. Pityrosporum folliculitis: the incidence of Pityrosporum ovale and the effect of antifungal drugs in steroid acne. Int. J. Dermatol 37,772–777 (1998).
   PubMed Web of Science ®Google Scholar
• Chang HS, Wzon YH, Chun IK, Kim YRTreatment of seborrhoeic dermatitits with itraconazole. Korean J. Dermatol 30,81–86 (1992).
   Google Scholar
• Masataro H. Treatment of seborrheic dermatitis with antifungal drugs. J. Clin. Exp. Med 173,1026–1027 (1995).
   Google Scholar
• Faergemann J. Treatment of sebopsoriasis with itraconazole. Mykosen 28,612–618 (1984).
   Google Scholar
• Morris-Jones R Sporothrichosis. Clin. Exp. Dermatol 27,427–431 (2002).
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Hajjeh R, Chapman SW Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society ofAmerica. Clin. Infect. Dis. 30, 684–687 (2000).
   PubMed Web of Science ®Google Scholar
• Kaufmann CA. Old and new therapies for sporotrichosis. Clirz. Infra. Dis. 21, 981–985 (1995).
   PubMed Web of Science ®Google Scholar
• Boni Eiz A, Carrasco-Gerard E, Saul A. Chromoblastomycosis: clinical and mycologic experience of 51 cases Mycoses 44,1–7 (2001).
   Web of Science ®Google Scholar
• Kumarasinghe SPW, Kumarasinghe MP Itraconazole pulse therapy inchromoblastomycosis. Eur. j Dermatol 10, 220–222 (2000).
   PubMed Web of Science ®Google Scholar
• Meis JFGM, Verweij PE. Current management of fungal infections. Drugs 61\(Suppl. 1), 3–25 (2001).
   Google Scholar
• •Overview of antifungal agents in the prophylactic and empiric treatment of systemic fungal infections.
   Google Scholar
• Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin. Infect. Dis. 30,696–709 (2000).
   PubMed Web of Science ®Google Scholar
• Giillot D. Intravenous itraconazolefollowed by oral itraconazole for the treatment of amphotericin B-refractory invasive pulmonary aspergillosis. Acta Haematol 109,111–118 (2003).
   PubMed Web of Science ®Google Scholar
• Caillot D, Bassaris H, McGeer A, et al Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease or AIDS. Clin. Infect. Dis. 33,83–90 (2001).
   PubMed Web of Science ®Google Scholar
• Groll Al-I. Itraconazole — perspectives for the management of invasive aspergillosis. Mzcoses 45\(Suppl. 3), 48–55 (2002).
   PubMedGoogle Scholar
• Wark PA, Hensley MJ, Saltos N, et al Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonaty aspergillosis: a randomized controlled trial. J. Allergy Clin. Immunot 111,952–957 (2003).
   PubMed Web of Science ®Google Scholar
• Moss RB. Allergic bronchopulmonaty aspergillosis. Clin. Rev. Allergy Immund 23,87–104 (2002).
   PubMed Web of Science ®Google Scholar
• Skov M, Hoiby N, Koch C. Itraconazole treatment of allergic bronchopulmonaty aspergillosis in patients with cystic fibrosis. Allergy 57,723–728 (2002).
   PubMed Web of Science ®Google Scholar
• De Beule K, De Doncker P, Cauwenbergh G, et al. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study. Mzcoses 31,476–485 (1988).
   PubMed Web of Science ®Google Scholar
• Mocherla S, Wheat U. Treatment of histoplasmosis. Semin. Respir. Infect. 16, 141–148 (2001).
   PubMedGoogle Scholar
• Kurowski R, Ostapchuk M. Overview of histoplasmosis. Am. Fam. Physician 66, 2247–2252 (2002).
   PubMed Web of Science ®Google Scholar
• Kaufmann CA. Management of histoplasmosis. Expert Opin. Pharmacother. 3,1067–1072 (2002).
   PubMedGoogle Scholar
• Lortholary O, Denning DW, DuPont B. Endemic mycoses: a treatment update. J. Arztimicrob. Chemother. 43,321–331 (1999).
   PubMed Web of Science ®Google Scholar
• Bradsher RW, Chapman SW Pappas PG. Blastomycosis. Infect. Dic. Clin. North Am. 17,21–40 (2003).
   PubMed Web of Science ®Google Scholar
• Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch. Intern. Med. 149, 2301–2308 (1989).
   PubMed Web of Science ®Google Scholar
• Hostetler JS, Denning DW, Stevens DA. US experience with itraconazole in Aspergillus, Cryptococcus and Histoplasma infections in the immunocompromised host. Chemotherapy 38\(Suppl. 1), 12–22 (1992).
   PubMedGoogle Scholar
• Deresinski SC. Coccidioidomycosis: efficacy of new agents and future prospects. Curn Opirz. Infect. Dis. 14,693–696 (2001).
   PubMed Web of Science ®Google Scholar
• Powderly WG. Coccidioidomycosis. J. Int. Assoc. Physiciarzs AIDS care 3,38–40 (1997).
   PubMedGoogle Scholar
• Galgiani JN, Ampel NM, Catanzaro A, Johnson RI-I, Stevens DA, Williams PL Practice guidelines for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin. Infect. Dis. 30, 658–661 (2000).
   PubMed Web of Science ®Google Scholar
• Diaz M, Puente R, de Hoyos LA, Cruz S. Itraconazole in the treatment of coccidioidomycosis. Chest 100,682–684 (1991).
   PubMed Web of Science ®Google Scholar
• Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA. Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. Am. J. Med. 89, 282–290 (1990).
   PubMed Web of Science ®Google Scholar
• Tucker RM, Denning DW, Arathoon EG, Rinaldi MG, Stevens DA. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. j Am. Acad Dermatol 23, 593–601 (1990).
   PubMed Web of Science ®Google Scholar
• Tucker RM, Denning DW, DuPont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann. Intern. Med. 112,108–112 (1990).
   PubMed Web of Science ®Google Scholar
• Naranjo MS, Trujillo M, Munema MI, Restrepo R, Gomez I, Restrepo A. Treatment of paracoccidioidomycosis with itraconazole. j Med Vet. Mycol 28,67–76(1990).
   PubMedGoogle Scholar
• Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: an update. Clin. Microbial Rev. 6,89–117 (1993).
   PubMed Web of Science ®Google Scholar
• Wong SSY, Wong KH, Hui WT, et al Differences in clinical and laboratory diagnostic characteristics of penicilliosis marneffei in human immunodeficiencyvirusand non-HIV-infectedpatients. j Clin. Microbial 39,4535–4540 (2001).
   PubMed Web of Science ®Google Scholar
• Nittayananta W. Penicilliosis marneffei: another AIDS defining disease in Southeast Asia. Oral Dis. 5,286–293 (1999).
   PubMed Web of Science ®Google Scholar
• Powderly WG. Penicilliosis. J. Int. Assoc. Physiciarzs AIDS Care 3,25–26 (1997).
   PubMedGoogle Scholar
• Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs 61 (Suppl. 1), 39-47(2001).
   PubMedGoogle Scholar
• •Clinical trial comparing prophylactic treattnent with itraconazole or amphotericin B + nystatin in neutropenic cancer patients.
   Google Scholar
• Boogaerts M, Maertens J, van Hoof A, et al Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients./ Antimicrob. Chemother. 48,97–103 (2001).
   Web of Science ®Google Scholar
• Myoken Y, Sugata T, Kyo T, Fujihara M, Mikami Y. Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. J. Periodontal 73,33–38 (2002).
   PubMed Web of Science ®Google Scholar
• Kageyama S, Masuya M, Tanaka I, et al Plasma concentration of itraconazole and its antifungal prophylactic efficacy in patients with neutropenia after chemotherapy for acute leukemia./ Infect. Chemother. 5,213–216 (1999).
   Google Scholar
• Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of antifungal infectsions in liver transplant recipients. Trarzsplarztation 74, 688–695 (2002).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Pranatharthi H, et al Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann. Intern. Med. 138,705–713 (2003).
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Arztimicrob. Agents Chemother. 44,1887–1893 (2000).
   PubMed Web of Science ®Google Scholar
• Gallin JI, Ailing DW, Malech HL, et al Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl. J. Med. 348,2416–2422 (2003).
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Prentice A, Gorschlueter M, et al Itraconazole prevents invasive fungal infection in neutropenic patients: evidence from a meta-analysis of 2711 patients. EBMT Istanbuh (2003) (Abstract 0262).
   Google Scholar
• Potter M. European experience with oral solution and intravenous itraconazole. Oncology 15,27–32 (2001).
   PubMedGoogle Scholar
• Boogaerts M, Winston DJ, Bow EJ, et al Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad spectrum antibacterial therapy. A randomized, controlled trial. Arzrz. Intern. Med. 135, 412–422 (2001).
   Web of Science ®Google Scholar
• van Cool R The cost of treating systemic fungal infections. Drugs 61 (Suppl. 1), 49–56 (2001).
   PubMedGoogle Scholar
• Ehninger G, Schuler U, Bammer S, et al Intravenous followed by oral itraconazole versus intravenous amphotericin B as empirical antifungal therapy for febrile neutropenic haematological cancer patients. 44th ASH Anrzual Meeting. PA, USA (2002) (Abstract 3631).
   Google Scholar
• Haria M, Bryson H1, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51,585–620 (1996).
   PubMed Web of Science ®Google Scholar
• Albreski D, Caldwell BD. A critical assessment of risk versus benefit of antifungal therapies. American Acadamy of Dermatology Annual Meeting (2002).
   Google Scholar
• Gupta Ak, Chwetzoff E, Del Rosso J, Baran R Hepatic safety of itraconazole. j Cutarz. Med. Surg. 6,210–213 (2002).
   PubMed Web of Science ®Google Scholar
• Katz HI. Drug interactions of the newer oral antifungal agents. Br. J. Dermatol 141 (Suppl. 56), 26–32 (1999).
   PubMedGoogle Scholar
• Hiruma M. Treatment of seborrhoeic dermatitis with antifungal drugs. J. Clin. Exp. DermatoL 173,1026–1027 (1995).
   Google Scholar
• Hiruma S. Treatment of face lesions in adult atopic dermatitis with oral antifungal itraconazole. Jpn Soc. Med Micology 74 (1995).
   Google Scholar
• Ikezawa Y, Ohnuma H, Ohuma S. Evaluation of oral therapy with antifungal drugs on refractory atopic dermatitis. Jprz. Ped. Dermatol 17,121–130 (1998).
   Google Scholar
• Remling R, Schnopp C, Weigl L, Ring J, Abeck D. Short-term itraconazole therapy in highly effective in severe cases of perioral dermatitis and rosacea. Eur. Acad.Dermatol Venereal 53 (2000).
   Google Scholar
• Mihara M, Hagari Y, Morimura T Treatment of pustolosis palmaris et plantaris with itraconazole.Jpn. Dermatol 108,139–145 (1998).
   Google Scholar
• Mihara M, Hagari Y, Morimura T, et al. Itraconazole as a new treatment for pustulosis palmaris et plantaris. Arch. Dermatol 134,639–640 (1998).
   PubMedGoogle Scholar